GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises GeneDx Holdings Corp. ('GeneDx' or 'the Company') (NASDAQ: WGS) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. GeneDx investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.
On February 5, 2025, Grizzly Research published a report titled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud,' alleging that GeneDx's reported growth was largely fabricated through fraudulent schemes. The report further asserted that GeneDx was deliberately exploiting Medicaid and Medicare systems to artificially inflate its revenue.
Following the release of this report, GeneDx's stock price experienced a decline of 6.7% on February 5, 2025, as investors reacted to the serious allegations.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.Admitted CA, NY and TX Bars
[email protected] 310-692-8883
www.portnoylaw.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Freshpet CEO Says 'Outsized Growth' Expected Despite Lowered Sales Target
Freshpet Inc. (NASDAQ:FRPT) stock rallied on Monday after it reported second-quarter 2025 earnings of 33 cents per share, beating the consensus estimate of 16 cents. Net sales rose 12.5% year-over-year to $264.7 million but missed the analyst estimate of $268.9 million. Sales growth was driven by a 10.8% increase in volume and a 1.7% improvement in price and mix. Net income was $16.4 million, reversing a net loss of $1.7 million in the year-ago quarter. Gross profit rose to $108.2 million, or 40.9% of net sales, up from $94.0 million, or 39.9%. Also Read: Adjusted gross margin improved to 46.9% from 45.9%. Adjusted EBITDA increased to $44.4 million from $35.1 million, with the margin expanding to 16.8% from 14.9%. SG&A expenses fell to $90.4 million from $95.7 million, or 34.1% of net sales versus 40.7% a year ago. Adjusted SG&A totaled $79.6 million, or 30.1% of net sales, compared to $72.9 million, or 31.0%, in the prior-year period. The company reported operating cash flow of $38.7 million year-to-date, down $9.1 million from the prior year, primarily due to one-time items and higher incentive compensation payments. Capital expenditures totaled $59.9 million through the second quarter. As of June 30, 2025, cash and cash equivalents stood at $243.7 million, with $396.2 million of debt outstanding. View more earnings on FRPT Operationally, Freshpet noted 170 basis points of improvement across quality, input, and logistics costs in the quarter. Ennis Kitchen became the company's most profitable facility. A new production line for bagged product is expected to be commissioned in Bethlehem in the fourth quarter of 2025, with potential retrofits starting in the second half of 2026. These upgrades are expected to reduce capital needs by at least $100 million between 2025 and 2026. Freshpet's household penetration rose 11% year-over-year, while its Most Valuable Pet Parents (MVPs) cohort increased 18%. The company added 1.4 million households over the past year and reported a 6% increase in buy rate. Store count reached 29,141 locations, with 24% of stores now hosting multiple fridges. 'Against a more challenging consumer sentiment backdrop, we continue to significantly outperform the dog food category – delivering both category leading sales growth and strong improvements in operations,' commented Billy Cyr, Freshpet's CEO. 'As a nimble growth company that is adapting to an economically constrained consumer, we are intensely focused on what we can control. That includes accelerating our advertising and distribution programs, reducing our capital expenditures, and strengthening our operations. On the other hand, we will be pragmatic about what we can't control, so we are revising our current year's net sales target and removing our long-term net sales target to match the environment we are facing today. We still believe we will deliver outsized growth for a long period of time, but we need to plan for the current economic realities. In total, we believe the actions we are taking position us well to create significant shareholder value and fulfill our mission to elevate the way we feed our pets with fresh food that nourishes all.' Outlook Freshpet updated its 2025 outlook, now expecting net sales growth of 13% to 16%, down from 15% to 18%. Adjusted EBITDA guidance remains unchanged at $190 million to $210 million. Capital expenditures are now forecast at approximately $175 million, reduced from the prior $225 million estimate. The company also updated its long-term guidance, removing its $1.8 billion net sales target for 2027 due to slower growth. However, it reaffirmed its other long-term goals: an adjusted gross margin of 48% and an adjusted EBITDA margin of 22%. Management anticipates the company will be free cash flow positive by 2026. The company expects to continue to deliver growth significantly in excess of the dog food category. Price Action: FRPT shares are trading higher by 8.15% to $71.22 at Monday's last check. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? FRESHPET (FRPT): Free Stock Analysis Report This article Freshpet CEO Says 'Outsized Growth' Expected Despite Lowered Sales Target originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
17 minutes ago
- Business Wire
U.S. News & World Report Names Cintas One of the Best Companies to Work For 2025-2026
CINCINNATI--(BUSINESS WIRE)-- Cintas Corporation (Nasdaq: CTAS) has been recognized by U.S. News & World Report as one of the best companies to work for in 2025-2026. This award demonstrates Cintas' strong commitment to creating a workplace culture where employee-partners feel supported and are given opportunities to thrive. 'At Cintas, we believe that our employee-partners are our greatest strength,' said Todd Schneider, Cintas President and CEO. 'This award recognizes their dedication to our culture, where employee-partners feel valued and empowered. We are always proud to receive these awards and be recognized as a great place to work.' To create this list, U.S. News evaluated the largest 5,000 publicly traded companies as of January 2025. The rankings are derived from an independent analysis of employee sentiment combined with publicly available data. The key factors evaluated included: Quality of pay and benefits Work-life balance and flexibility Job and company stability Physical and psychological comfort Belongingness and esteem Career opportunities and professional development Cintas was also recognized in one of the major categories, including Best Workplaces in the Midwest. About Cintas Corporation Cintas Corporation helps more than one million businesses of all types and sizes get Ready™ to open their doors with confidence every day by providing products and services that help keep their customers' facilities and employees clean, safe, and looking their best. With offerings including uniforms, mats, mops, towels, restroom supplies, workplace water services, first aid and safety products, eye-wash stations, safety training, fire extinguishers, sprinkler systems and alarm service, Cintas helps customers get Ready for the Workday®. Headquartered in Cincinnati, Cintas is a publicly held Fortune 500 company traded over the Nasdaq Global Select Market under the symbol CTAS and is a component of both the Standard & Poor's 500 Index and Nasdaq-100 Index.
Yahoo
20 minutes ago
- Yahoo
Afaxys Secures $8 Million to Advance Mission and Accelerate Growth Strategy
CHARLESTON, S.C., Aug. 4, 2025 /PRNewswire/ -- Afaxys, Inc., a socially conscious healthcare company focused on serving the reproductive health needs of public health professionals and their patients, announces it has secured $8 million in new funding from two large foundations to support its mission and propel its growth strategy. The capital includes a $3 million program-related investment (PRI) from the David and Lucile Packard Foundation and a $5 million grant from an anonymous foundation. This marks the third investment from the Packard Foundation since Afaxys was founded in 2008, underscoring the long-standing partnership and confidence in Afaxys' impact-driven model. "Through our mission-based investments, Afaxys has grown into a durable and financially sustainable force in the market that will continue to actively ensure and continually expand reproductive health access for all patients, especially those served by public health providers," said Susan Phinney-Silver, Mission Investing Director at the David and Lucile Packard Foundation. The new funding serves as a catalyst for growth as Afaxys continues its mission of providing millions of women in the United States access to affordable contraception. Afaxys is the only organization of its kind with an established, nationwide distribution infrastructure serving public health clinics. Afaxys plays a critical role in ensuring reliable supply chains for clinics that serve Medicaid and Title X patients. The funding will be used to complete the development of a novel contraceptive product, specifically designed to address the needs of marginalized communities and the more than 19 million women living in contraceptive deserts. "Access to quality reproductive healthcare has never been more critical. We are excited to partner with these esteemed foundations to further the Afaxys mission and ensure that access to reproductive healthcare is a right, not a privilege," said Ronda Dean, CEO of Afaxys, Inc. About Afaxys Afaxys, a Public Benefit Corporation, uniquely partners with public health and private industry to ensure healthcare professionals have stable pricing and reliable access to the products and services they need to care for their patients. The Afaxys enterprise comprises a family of companies that operate under three wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Drug Development, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market. Afaxys Drug Development provides development and regulatory services of pharmaceutical products with a focus on rapid and efficient launch readiness to promote Afaxys' strategic goal of cost-conscious product commercialization. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization. For more information, visit Forward-Looking Statements The statements in this press release that are not historical facts constitute "forward-looking statements" as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made. Afaxys Media ContactGreen Room Communicationsgr_afaxys@ View original content to download multimedia: SOURCE Afaxys, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
